Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.42 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.41 |
| ▸ | SHMT1 | P34896 | 1/20 | 0.37 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.35 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | ARG1 | P05089 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30645458 | 0.84 | SMN1; SMN2 (0.44) | SMN1; SMN2EPHX2C3AR1SHMT1CPB2 | |
| SCHEMBL27632265 | 0.84 | SMN1; SMN2 (0.45) | SMN1; SMN2EPHX2CPB2EPHX1 | |
| SCHEMBL31416512 | 0.82 | SMN1; SMN2 (0.42) | SMN1; SMN2EPHX2C3AR1SHMT1CPB2 | |
| SCHEMBL1345737 | 0.82 | EPHX2 (0.37) | SMN1; SMN2EPHX2C3AR1CPB2MEN1 | |
| SCHEMBL7628167 | 0.82 | EPHX2 (0.37) | SMN1; SMN2EPHX2C3AR1CPB2MEN1 | |
| SCHEMBL32665433 | 0.78 | C3AR1 (0.37) | SMN1; SMN2EPHX2C3AR1SHMT1CPB2 | |
| SCHEMBL21167241 | 0.78 | KMT2A (0.41) | SMN1; SMN2EPHX2KMT2ALMNA | |
| SCHEMBL9181564 | 0.76 | CPB2 (0.55) | CPB2 | |
| SCHEMBL9181567 | 0.76 | CPB2 (0.55) | CPB2 | |
| SCHEMBL6562366 | 0.75 | GRIN1 (0.47) | SMN1; SMN2EPHX2C3AR1CPB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026099502-A1 | NOVEL DRUG CONJUGATES FOR TESTING CELLULAR DRUG UPTAKE | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2026-05-15 | — | — | WO | claimed |
| WO-2025120085-A1 | MODULAR LINKER COMPOUND FOR TARGET-BINDING DRUG CONJUGATES | HEIDELBERG PHARMA RESEARCH GMBH (DE) | 2025-06-12 | — | — | WO | claimed |
| US-20250186606-A1 | MODULAR LINKER COMPOUND FOR TARGET-BINDING DRUG CONJUGATES | HEIDELBERG PHARMA RESEARCH GMBH (DE) | 2025-06-12 | — | — | US | claimed |
| US-20250177546-A1 | ROR1-TARGETED BINDING MOLECULE AND USE THEREOF | HANGZHOU ZHONGMEIHUADONG PHARMACEUTICAL CO., LTD. (CN) | 2025-06-05 | — | — | US | claimed |
| WO-2025109097-A2 | NOVEL NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE INHIBITORS AND USES THEREOF | HEIDELBERG PHARMA RESEARCH GMBH (DE) | 2025-05-30 | — | — | WO | claimed |
| US-20250171419-A1 | NOVEL NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE INHIBITORS AND USES THEREOF | HEIDELBERG PHARMA RESEARCH GMBH (DE) | 2025-05-29 | — | — | US | claimed |
| WO-2025031307-A1 | MULTIDRUG LINKER AND ANTIBODY-DRUG CONJUGATE | 上海华藕生物医药有限公司 | 2025-02-13 | — | — | WO | claimed |
| CN-119371541-A | ROR 1-targeted binding molecule and application thereof | 杭州中美华东制药有限公司 | 2025-01-28 | — | — | CN | claimed |
| EP-4491632-A1 | ROR1-TARGETED BINDING MOLECULE AND USE THEREOF | Sanyou Biopharmaceuticals Co., Ltd. (CN) | 2025-01-15 | — | — | EP | claimed |
| US-20240384269-A1 | COMPOSITIONS CONTAINING NUCLEIC ACID NANOPARTICLES AND PROCESSES RELATED TO ALTERATION OF THEIR PHYSIOCHEMICAL CHARACTERISTICS | Sixfold Bioscience Ltd. (GB) | 2024-11-21 | — | — | US | claimed |
| CN-118574845-A | ROR 1-targeted antibody or antigen binding fragment thereof and application thereof | 杭州中美华东制药有限公司 | 2024-08-30 | — | — | CN | claimed |
| EP-4404974-A1 | ANTIBODY-DRUG CONJUGATES | Spirea Limited (GB) | 2024-07-31 | — | — | EP | claimed |
| EP-4323517-A2 | COMPOSITIONS CONTAINING NUCLEIC ACID NANOPARTICLES AND PROCESSES RELATED TO ALTERATION OF THEIR PHYSICOCHEMICAL CHARACTERISTICS | Sixfold Bioscience Ltd. (GB) | 2024-02-21 | — | — | EP | claimed |
| WO-2023169328-A1 | ROR1-TARGETED BINDING MOLECULE AND USE THEREOF | 三优生物医药(上海)有限公司 | 2023-09-14 | — | — | WO | claimed |
| WO-2023047090-A1 | ANTIBODY-DRUG CONJUGATES | SPIREA LIMITED (GB) | 2023-03-30 | — | — | WO | claimed |
| WO-2022219409-A2 | COMPOSITIONS CONTAINING NUCLEIC ACID NANOPARTICLES AND PROCESSES RELATED TO ALTERATION OF THEIR PHYSICOCHEMICAL CHARACTERISTICS | Sixfold Bioscience Ltd. (GB) | 2022-10-20 | — | — | WO | claimed |
| WO-2026100671-A1 | ANTI-GPRC5A ANTIBODY AND USES THEREOF | リベロセラ株式会社 | 2026-05-15 | — | — | WO | disclosed |
| WO-2026099502-A1 | NOVEL DRUG CONJUGATES FOR TESTING CELLULAR DRUG UPTAKE | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2026-05-15 | — | — | WO | disclosed |
| WO-2023047090-A1 | ANTIBODY-DRUG CONJUGATES | SPIREA LIMITED (GB) | 2023-03-30 | — | — | WO | disclosed |
| WO-2022164942-A1 | PNMA2-BASED CAPSIDS AND USES THEREOF | VNV NEWCO INC. (US) | 2022-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250186606-A1 | MODULAR LINKER COMPOUND FOR TARGET-BINDING DRUG CONJUGATES | BCR, TBCD, TBC1D5 | SMN1; SMN2 3568/4885EPHX2 2482/4885C3AR1 2266/4885 |
| US-20250177546-A1 | ROR1-TARGETED BINDING MOLECULE AND USE THEREOF | RORB, RORA, RORC | SMN1; SMN2 3377/4885EPHX2 1499/4885C3AR1 2009/4885 |
| US-20250171419-A1 | NOVEL NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE INHIBITORS AND USES THEREOF | NAMPT, NAPRT, NNMT | SMN1; SMN2 2735/4885EPHX2 2212/4885C3AR1 2379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.